Fabian Sommer/Image courtesy of Getty Images

Evidence has shown that Pfizer’s COVID-19 antiviral treatment pill, paxlovide, may not be beneficial in vaccinated individuals, the pharmaceutical company said.

On Thursday, the company released Results of a new study On Paxlovide. Researchers reviewed 721 vaccinated adults with at least one exposure to Covid-19 and found a “non-significant” reduction in the risk of hospitalization or death when treated with the antiviral pill.

However, experts say the results confirm that the use of paxlovide can significantly reduce severe COVID symptoms in patients with serious medical conditions.

“Paxlovide is targeted at high-risk individuals, so it’s not surprising to me that it doesn’t benefit low-risk individuals,” said Dr. Amesh Adalja, an infectious disease specialist at Johns Hopkins University. He told the Center for Health Security. ABC News.

“It is estimated that up to 40-50% of people in the world are at high risk, we believe that there is a great need for treatment options to help fight this disease, and we are prioritizing efforts to advance the development of paxlovid,” Pfizer CEO Albert Burla said in a release.

Never miss a story – subscribe PeopleFree daily newspaper Get the best updates people have to offer, from celebrity news to heartwarming human stories.



Pfizer/AFP via Getty Pfizer’s covid-19 antiviral treatment paxlovide

The new information comes after a week Food and Drug Administration Emergency Use Permit Amended. For paxlovide, it allows pharmacists across the United States to prescribe the covid treatment for eligible patients.

Individuals who have tested positive for COVID-19 and want to determine their eligibility to take paxlovide can bring their current medications and health records, which list kidney and liver problems, to their pharmacist for review. Patients with reduced kidney function may require a lower dose of Paxlovid, according to the FDA.

“Pharmacists recognize the important role pharmacists have played and continue to play,” Dr. Patricia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement. “Because paxlovide must be taken within five days of symptom onset, allowing state-licensed pharmacists to prescribe paxlovide may expand access to timely treatment for some patients eligible for this drug for treatment of COVID-19.”

RELATED: Dr. Fauci takes second course of Paxlovide after experiencing Covid-19 relapse

In April, the Biden administration announced plans to make Paxlovide “widely available,” White House covid-19 response coordinator Dr. Ashish Jha said on Twitter.

“What are we working on? Many more areas including pax for additional treatment, for providers to routinely use it for eligible patients, and more,” Jha said. He wrote by the time. “Paxolide is incredibly effective at preventing adverse outcomes. We’re getting it for the American people.”

A treatment trial was launched earlier this year to make it easier for Americans to get treatment for Covid. “One-Stop Sites” To be tested for covid-19 and to be prescribed free oral antiviral medications.

The FDA initially approved paxlovide Emergency use permit In November 2021, it will be used in patients aged 12 or older with medical conditions at high risk of severe covid-19 disease.

Each pack of Paxlovide contains 30 tablets taken over five days. according to Yale medicineThe pill is effective against the highly contagious Omicron strain of Covid-19.

Scott Roberts, an infectious disease specialist at Yale Medicine, believes the pill “shows clear benefit.”

“I think it’s the beginning of a game changer,” Roberts said. “It’s actually the first effective oral antiviral pill for this virus. It shows clear benefit, and it prevents hospitalization and death in people at high risk.”

Source link

Leave a Reply

Your email address will not be published.